Cargando…
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches—Focus on EZH2-Targeted Drugs
PURPOSE OF REVIEW: Epigenetic modifier gene mutations are common in patients with follicular lymphoma. Here we review the pathogenesis of these mutations and how they are targeted by epigenetic drugs including EZH2 inhibitors in both mutated and wild-type disease. RECENT FINDINGS: The use of EZH2 in...
Autores principales: | Longley, Jemma, Johnson, Peter W. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088902/ https://www.ncbi.nlm.nih.gov/pubmed/33937922 http://dx.doi.org/10.1007/s11912-021-01076-0 |
Ejemplares similares
-
The Changing Landscape of Lymphoma Associated with HIV Infection
por: Hübel, Kai
Publicado: (2020) -
Richter Syndrome
por: Condoluci, Adalgisa, et al.
Publicado: (2021) -
Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin’s Lymphoma?
por: Johnson, Peter, et al.
Publicado: (2017) -
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021) -
Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)